menu
    • menu
    [{"orgOrder":0,"company":"Mosaic ImmunoEngineering","sponsor":"University of California San Diego","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"MIE-101","moa":"TLR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mosaic ImmunoEngineering","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral","sponsorNew":"Mosaic ImmunoEngineering \/ University of California San Diego","highestDevelopmentStatusID":"5","companyTruncated":"Mosaic ImmunoEngineering \/ University of California San Diego"},{"orgOrder":0,"company":"Mosaic ImmunoEngineering","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"MIE-101","moa":"TLR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mosaic ImmunoEngineering","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral","sponsorNew":"Mosaic ImmunoEngineering \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mosaic ImmunoEngineering \/ Not Applicable"},{"orgOrder":0,"company":"Mosaic ImmunoEngineering","sponsor":"Oncotelic Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Acquisition","leadProduct":"Trabedersen","moa":"TGF beta-2","graph1":"Oncology","graph2":"Phase II","graph3":"Mosaic ImmunoEngineering","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mosaic ImmunoEngineering \/ Mosaic ImmunoEngineering","highestDevelopmentStatusID":"8","companyTruncated":"Mosaic ImmunoEngineering \/ Mosaic ImmunoEngineering"}]

    Find Clinical Drug Pipeline Developments & Deals by Mosaic ImmunoEngineering

    Menu

    Mosaic ImmunoEngineering

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Mosaic ImmunoEngineering

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Mosaic ImmunoEngineering

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trabedersen

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Oncotelic Therapeutics

                            Deal Size : $15.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Oncotelic to Sell Necroptosis Cancer Therapy to Mosaic ImmunoEngineering

                            Details : Through the acquisition, the company will utilize OT-101 (trabedersen), currently under investigation in adult patients, for brain cancer and diffuse intrinsic pontine glioma.

                            Product Name : OT-101

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            April 29, 2024

                            Lead Product(s) : Trabedersen

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Oncotelic Therapeutics

                            Deal Size : $15.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Mosaic ImmunoEngineering

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Mosaic ImmunoEngineering

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MIE-101

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mosaic ImmunoEngineering's Lead Immuno-Oncology Candidate MIE-101 Highlighted in Keynote Presentation

                            Details : MIE-101, a Cowpea mosaic virus has shown to engage multiple Toll-like receptors on host immune cells in the tumor that have evolved to detect foreign invaders enhanced antitumor effects when combined with immune checkpoint inhibitors and other standard ...

                            Product Name : MIE-101

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 01, 2021

                            Lead Product(s) : MIE-101

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Mosaic ImmunoEngineering

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Mosaic ImmunoEngineering

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MIE-101

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : University of California San Diego

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Mosaic ImmunoEngineering Expands Immuno-Oncology Platform Through New Technology Licensing Agreement with the ...

                            Details : Under the agreement, Mosaic has licensed rights to develop and commercialize new treatment candidates including lead product, MIE-101, is derived from the cowpea mosaic virus (CPMV), that broaden the scope and capabilities of the protein nanoparticle pla...

                            Product Name : MIE-101

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 06, 2021

                            Lead Product(s) : MIE-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : University of California San Diego

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth